Van Naarden Jacob, EVP and President of Lilly Oncology, made one open market purchase of Eli Lilly ($LLY) shares worth $647,360 in the last year, with the most recent on August 13, 2025. This ranks 706th among nearly 5,000 insiders, below the average of $1.46 million per buyer and 3.3 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 9, 2026 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | A | Common Stock | 4866 | $1044.67 | 36,270.4980 | 945,383,757 | 15.49% | 0.00% |
| Feb. 1, 2026 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | M | Common Stock | 4108 | $0.00 | 33,313.9850 | 945,383,757 | 14.07% | 0.00% |
| Feb. 1, 2026 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | M | Restricted Stock Unit | 4108 | $0.00 | 0.0000 | 945,383,757 | 100.00% | 0.00% |
| Feb. 1, 2026 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | F | Common Stock | 1909 | $1037.15 | 31,404.6100 | 945,383,757 | 5.73% | 0.00% |
| Aug. 13, 2025 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Lilly Oncology | P | Common Stock | 1000 | $647.36 | 29,205.9850 | 948,169,999 | 3.55% | 0.00% |
| Feb. 10, 2025 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Lilly Oncology | A | Restricted Stock Unit | 4108 | $0.00 | 4,108.0000 | 0 | 9999.99% | 0.00% |
| Feb. 10, 2025 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Lilly Oncology | A | Common Stock | 6104 | $868.88 | 28,205.9850 | 0 | 27.62% | 0.00% |
| Feb. 1, 2025 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Lilly Oncology | M | Restricted Stock Unit | 3023 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 1, 2025 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Lilly Oncology | F | Common Stock | 1410 | $811.08 | 22,102.1610 | 0 | 6.00% | 0.00% |
| Feb. 1, 2025 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Lilly Oncology | M | Common Stock | 3023 | $0.00 | 23,512.0000 | 0 | 14.75% | 0.00% |
| Oct. 31, 2024 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Lilly Oncology | G | Common Stock | 4302 | $0.00 | 20,489.0000 | 0 | 17.35% | 0.00% |
| Feb. 12, 2024 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Loxo@Lilly | A | Common Stock | 2369 | $737.26 | 20,489.0000 | 0 | 13.07% | 0.00% |
| Feb. 12, 2024 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Loxo@Lilly | A | Restricted Stock Unit | 3023 | $0.00 | 3,023.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Loxo@Lilly | F | Common Stock | 1685 | $645.61 | 18,120.0000 | 0 | 8.51% | 0.00% |
| Feb. 1, 2024 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Loxo@Lilly | M | Restricted Stock Unit | 3618 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 1, 2024 | ELI LILLY & Co | $LLY | Van Naarden Jacob | EVP & Pres., Loxo@Lilly | M | Common Stock | 3618 | $0.00 | 19,805.0000 | 0 | 22.35% | 0.00% |